Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 10/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 8/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 8/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.79 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.78 |
| ▸ | PRKDC | P78527 | 2/20 | 0.77 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.77 |
| ▸ | AKT1 | P31749 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22028121 | 0.92 | PIK3CB (0.85) | MTORPIK3CBPIK3CGPIK3CAPIK3CD | |
| SCHEMBL3094883 | 0.92 | PIK3CG (0.85) | MTORPIK3CBPIK3CGPIK3CAPIK3CD | |
| SCHEMBL22030451 | 0.89 | PIK3CB (0.82) | MTORPIK3CBPIK3CGPIK3CAPIK3CD | |
| SCHEMBL1543749 | 0.88 | PIK3CA (1.00) | MTORPIK3CBPIK3CGPIK3CAPIK3CD | |
| SCHEMBL1543320 | 0.88 | PIK3CA (1.00) | MTORPIK3CBPIK3CGPIK3CAPIK3CD | |
| SCHEMBL21189460 | 0.87 | PIK3CB (0.77) | MTORPIK3CBPIK3CGPIK3CAPIK3CD | |
| SCHEMBL1543534 | 0.87 | MTOR (1.00) | MTORPIK3CBPIK3CGPIK3CAPIK3CD | |
| SCHEMBL1543560 | 0.87 | PIK3CA (1.00) | MTORPIK3CBPIK3CGPIK3CAPIK3CD | |
| SCHEMBL1543532 | 0.86 | PIK3CA (1.00) | MTORPIK3CBPIK3CGPIK3CAPIK3CD | |
| SCHEMBL1542205 | 0.85 | PIK3CA (1.00) | MTORPIK3CBPIK3CGPIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | claimed |
| EP-2307400-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | claimed |
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| EP-2307400-B1 | INHIBITORS OF PI3 KINASE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| EP-2307400-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | MTOR, PIK3CA, MAPKAP1 | MTOR 1/4885PIK3CB 16/4885PIK3CG 12/4885 |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3R1, PIK3R5 | MTOR 34/4885PIK3CB 11/4885PIK3CG 7/4885 |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | MTOR, PIK3CA, MAPKAP1 | MTOR 1/4885PIK3CB 16/4885PIK3CG 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.